Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas

Background. No established chemotherapeutic regimen exists for the treatment of recurrent malignant gliomas (rMGs). Herein, we report the activity and safety results of the bevacizumab (B) plus fotemustine (FTM) combination for the treatment of rMGs. Patients and Methods. An induction phase consiste...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaccaro, V., Fabi, A., Vidiri, A., Giannarelli, D., Metro, G., Telera, S., Vari, S., Piludu, F., Carosi, M. A., Villani, V., Cognetti, F., Pompili, A., Marucci, L., Carapella, C. M., Pace, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024398/
https://www.ncbi.nlm.nih.gov/pubmed/24877084
http://dx.doi.org/10.1155/2014/351252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024398/
https://www.ncbi.nlm.nih.gov/pubmed/24877084
http://dx.doi.org/10.1155/2014/351252

Ejemplares similares